TransUnion's EVP, Russell Heather J, sells 5337 shares at $90.01/share on 2025-09-05.

TransUnion (TRU) recently announced that EVP and Chief Legal Officer Russell Heather J sold 5,337 shares at a price of $90.01 per share on September 5, 2025.

TransUnion (TRU) recently saw its Executive Vice President and Chief Legal Officer, Russell Heather J, sell 5,337 shares of the company's stock at a price of $90.01 per share on September 5, 2025. The transaction, disclosed in a filing with the SEC, represents a significant reduction in the insider's position, which previously consisted of 65,592 shares valued at approximately $5,648,783.40.

The sale comes amidst a period of positive earnings reports and analyst upgrades for TransUnion. The company reported earnings per share (EPS) of $1.08 for the last quarter, exceeding expectations and marking a 9.5% increase in revenue compared to the previous year. This robust performance has been reflected in upward revisions in broker ratings, with several analysts upgrading their ratings and target prices for the stock [3].

The latest earnings report also saw TransUnion declare a quarterly dividend of $0.115, reflecting a 0.5% yield and an ongoing dividend payout ratio of 23.00%. The company's financial services have been bolstered by strategic partnerships, such as its collaboration with Truework to expand income and employment verification solutions, which has led to a 3.9% increase in shares following the announcement [2].

Despite the positive news, TransUnion's stock has experienced volatility, with 14 moves greater than 5% over the last year. The company's shares are currently trading at $86.09, down 0.4% from Wednesday's close, but still 14.3% below its 52-week high of $108.67 from October 2024. Investors who bought $1,000 worth of TransUnion's shares five years ago would now be looking at an investment worth $1,122 [2].

Investors should monitor TransUnion closely as it approaches its earnings reports for the fiscal year 2025. The company's projected earnings growth and positive analyst revisions suggest that it is well-positioned for continued success.

References:
[1] https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-hit-52-week-high-can-run-continue
[2] https://finance.yahoo.com/news/transunion-tru-stock-trades-why-154610707.html
[3] https://www.marketbeat.com/instant-alerts/transunion-nysetru-insider-steven-chaouki-sells-1000-shares-2025-09-03/